Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus

Leite, Nathalie C.; Salles, Gil F.; Araújo, Antônio Luis Eiras de; Villela-Nogueira, Cristiane Alves; Cardoso, Claudia R.L.

doi:10.1111/j.1478-3231.2008.01718.x

Cited by 450 publications

(328 citation statements)

References 34 publications

Supporting

Mentioning

300

Contrasting

Unclassified

Order By: Relevance

“…4 An ultrasonographic study of patients with T2DM showed a 69% prevalence of NAFLD. 21 In another study, 127 of 204 diabetic patients displayed fatty infiltration on ultrasound, and 87% of the patients with fatty infiltration who consented to biopsy had histologic confirmation of NAFLD. 22 High serum triglyceride levels and low serum HDL levels are very common in patients with NAFLD.…”

Section: Incidence and Prevalence In The General Populationmentioning

confidence: 98%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

Section: Incidence and Prevalence In The General Populationmentioning

confidence: 98%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

“…In one recent study done of patients with type II DM, it was noted that there was a 69% prevalence of NAFLD on ultrasound imaging. 35 It is also important to note that NASH and advanced fibrosis are often observed in diabetic patients that are asymptomatic clinically and in some cases with normal liver enzymes. Another recent study from India showed that 127 of 204 diabetic patients displayed fatty liver on ultrasound and among those who consented to a liver biopsy and had fatty liver on ultrasound, 87% had biopsy-proven NAFLD.…”

Section: Diabetes Mellitus Type IImentioning

confidence: 99%

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease

Mishra¹,

Younossi²

2012

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease burden across the world. By definition, although the histopathologic features of NAFLD are identical to that of alcoholic liver disease, its diagnosis requires absence of significant alcohol use and absence of other causes of chronic liver disease. We now know that NAFLD is not simply a disease of the Western world. It is manifested across the world, in varying rates, across gender, across varying ethnicities, and in its association with other host factors. In this review article, the definition of NAFLD, its spectrum, ranging from mild steatosis to hepatocellular injury and inflammation defined as non-alcoholic steatohepatitis (NASH) is discussed. Mild steatosis is generally a stable disease whereas NASH can be progressive. Based on current published literature, current incidence and prevalence of NAFLD and NASH are discussed. It is also accepted that these processes will continue to increase in prevalence with the rise of obesity, type II diabetes, and associated metabolic syndrome. Some of the risk factors have been well-established and are discussed. In addition, this review also presents emerging associations with other risk factors for NAFLD. Natural history of NAFLD is variable depending upon the histologic subtypes and other underlying comorbidities and is discussed in this review as well. (J CLIN EXP HEPATOL 2012;2:135-144)

show abstract

“…The prevalence of NAFLD has increased dramatically in recent years and affects 15-30% of the general population (Bellentani & Marino 2009). However, in individuals with type 2 diabetes (T2DM), the prevalence of NAFLD is up to 70% (Targher et al 2007, Leite et al 2009, Prashanth et al 2009). …”

Section: Introductionmentioning

confidence: 99%

Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening

Yin¹,

Zheng²,

Pan³

et al. 2015

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Oxidative stress is considered to be an important factor in producing lethal hepatocyte injury associated with nonalcoholic fatty liver disease (NAFLD). Glucose fluctuation, more pronounced in patients with diabetes, has been recognized as an even stronger oxidative stress inducer than the sustained hyperglycemia. Here, we investigated the role of glucose variability in the development of the NAFLD based on hepatocyte apoptosis and possible mechanisms. To achieve this goal we studied C57BL/6J mice that were maintained on a high fat diet (HFD) and injected with glucose (3 g/kg) twice daily to induce intermittent high glucose (IHG). We also studied hepatic L02 cells incubated with palmitic acid (PA) to induce steatosis. The following experimental groups were compared: normal glucose (NG), sustained high glucose (SHG) and IHG with or without PA. We found that, although hepatic enzyme levels and liver lipid deposition were comparable between HFD mice injected with glucose or saline, the glucose injected mice displayed marked hepatocyte apoptosis and inflammation, accompanied by increased lipid peroxide in liver. In vitro, in the presence of PA, IHG increased L02 cell apoptosis and oxidative stress and produced pronounced mitochondrial dysfunction relative to the NG and SHG groups. Furthermore, treatment with the mitochondrial permeability transition (MPT) inhibitor, cyclosporin A (1.5 mmol/l), prevented mitochondrial dysfunction, oxidative stress and hepatocyte apoptosis. Our data suggests that IHG under lipotoxicity might contribute to the development of NAFLD by increasing oxidative stress and hepatocyte apoptosis via MPT and its related mitochondrial dysfunction.

show abstract

Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus

Cited by 450 publications

References 34 publications

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease

Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening

Contact Info

Product

Resources

About